BioAegis Therapeutics: Funding, Investors & Team (Oct 2026)
BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role has been studied in animals and humans. Based on discoveries by Dr. Thomas Stossel and others, the body’s natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and catastrophic consequences like multiple organ failure, shock and death. Systemic inflammation causes morbidity and mortality in a myriad of diseases including rare orphan indications and major acute and chronic diseases such as trauma, burns, renal disease and sepsis. Replacement of plasma gelsolin holds great promise for patients suffering from severe conditions with high unmet medical needs. BioAegis is developing high value, biomarker-directed treatments across a range of indications.
BioAegis Therapeutics has raised $22.0M across 1 funding round on record, the most recent an undisclosed round of $22.0M announced in Mar 2022.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioAegis Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2022.
BioAegis Therapeutics Funding Rounds
BioAegis Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
BioAegis Therapeutics Funding Compared to Other Biotechnology Startups
BioAegis Therapeutics' latest round of $22.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioAegis Therapeutics in Biotechnology and Morristown
Companies Similar to BioAegis Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
BioAegis Therapeutics Funding FAQs
What does BioAegis Therapeutics do?
BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role has been studied in animals and humans. Based on discoveries by Dr. Thomas Stossel and others, the body’s natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and catastrophic consequences like multiple organ failure, shock and death. Systemic inflammation causes morbidity and mortality in a myriad of diseases including rare orphan indications and major acute and chronic diseases such as trauma, burns, renal disease and sepsis. Replacement of plasma gelsolin holds great promise for patients suffering from severe conditions with high unmet medical needs. BioAegis is developing high value, biomarker-directed treatments across a range of indications.
How much funding has BioAegis Therapeutics raised?
BioAegis Therapeutics has raised $22.0M across 1 round on record. The most recent is an undisclosed round of $22.0M announced in Mar 2022.
When did BioAegis Therapeutics last raise funding?
BioAegis Therapeutics' most recent funding round on record is an undisclosed round of $22.0M, announced in Mar 2022.
Who is the CEO of BioAegis Therapeutics?
Susan Levinson is listed as CEO at BioAegis Therapeutics.
Where is BioAegis Therapeutics headquartered?
BioAegis Therapeutics is based in Morristown, New Jersey, United States.
How many employees does BioAegis Therapeutics have?
BioAegis Therapeutics is in the 11-50 employee band.
How does BioAegis Therapeutics' funding compare to other Biotechnology startups?
BioAegis Therapeutics' latest round of $22.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's BioAegis Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioAegis Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.